Model releases · · 2 min read

Google DeepMind AlphaGenome 2 model reads DNA effects by cell type

Google DeepMind's AlphaGenome 2 model predicts genetic variant effects per cell type, not bulk tissue. Here is what it means for marketers and growth teams.

Takeaway AlphaGenome 2 is a research model, not a marketing tool; treat it as a signal of where Google's agent platform and science AI are heading.

The Google DeepMind AlphaGenome 2 model changes the unit of analysis in genomics AI. Instead of estimating how a genetic variant behaves across a blended tissue sample, it looks at individual cell types.

This is a science release, not a marketing one. Still, founders and growth teams who follow Google's model roadmap have reasons to read it.

What shipped

Google DeepMind introduced AlphaGenome 2, a model that evaluates genetic variants for specific cell types. The previous approach produced predictions averaged over bulk tissue. The new version narrows that down to single cell type resolution.

The company also plans to bring the model into Antigravity, Google's agentic platform.

What is new

The main change is resolution. Bulk tissue predictions can hide effects that matter only in one kind of cell. Working per cell type is meant to surface those effects.

The training set is large: over 107 million cell profiles, according to the report. The source says the model flags close to double the number of variants linked to disease compared with the first AlphaGenome.

Benchmarks (developer-reported)

The announcement summary does not list benchmark results beyond the comparison with the earlier model noted above; see the source for details.

Price and access

Access is through an API and is limited to noncommercial research. The announcement summary does not state pricing. Commercial use is not part of the current offer.

What it means for marketing

For most teams, nothing changes in the next quarter. A noncommercial research license means you cannot build a product or campaign workflow on it today.

There are three practical points.

Health and biotech messaging. If you sell into life sciences, expect buyers to ask about cell-level resolution and agent-based research tooling. Update positioning and sales content to speak to that shift in precision, and avoid claims that rely on this model until commercial terms exist.

Content and search. Coverage will pick up terms such as single cell resolution and variant effect prediction. Companies with real expertise can publish explainers that answer the questions researchers and analysts will search for. Keep claims tied to what the developer reported.

Platform watching. The planned Antigravity integration suggests Google is placing specialist models inside its agent tooling. Teams that depend on Google's ecosystem should track how that platform evolves, since it may eventually shape how specialist data work is automated.

Until licensing opens up, the sensible step is to monitor, not to budget for it.

Source

The Decoder: Google Deepmind shifts genomics AI from bulk tissue predictions to single cell type resolution with AlphaGenome 2 (2026-11-12)

Written by the AI CMO OS newsroom from the publisher's report. Facts and figures are as reported by the source; read the original for full details.

More in Model releases